Anna Hockaday

1.7k total citations
31 papers, 433 citations indexed

About

Anna Hockaday is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Anna Hockaday has authored 31 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 16 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Anna Hockaday's work include Multiple Myeloma Research and Treatments (17 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Lymphoma Diagnosis and Treatment (10 papers). Anna Hockaday is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Lymphoma Diagnosis and Treatment (10 papers). Anna Hockaday collaborates with scholars based in United Kingdom, United States and Italy. Anna Hockaday's co-authors include David A. Cairns, Gordon Cook, Martin Kaiser, Charlotte Pawlyn, Walter M. Gregory, Faith E. Davies, Mark T. Drayson, Graham Jackson, Gareth J. Morgan and Roger G. Owen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Anna Hockaday

24 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Hockaday United Kingdom	10	344	236	170	129	80	31	433
Maria Gavino United States	7	484 1.4×	342 1.4×	258 1.5×	152 1.2×	80 1.0×	10	591
Mariella Grasso Italy	11	413 1.2×	330 1.4×	249 1.5×	79 0.6×	51 0.6×	29	539
Christy Samaras United States	13	264 0.8×	302 1.3×	189 1.1×	97 0.8×	16 0.2×	57	437
Faiza Zafar United States	11	447 1.3×	370 1.6×	262 1.5×	60 0.5×	21 0.3×	40	507
Angelo Belotti Italy	14	312 0.9×	245 1.0×	201 1.2×	82 0.6×	55 0.7×	41	451
Rony Abou Jawde United States	8	261 0.8×	91 0.4×	100 0.6×	100 0.8×	7 0.1×	11	355
Nuriet K. Khuageva Russia	8	563 1.6×	445 1.9×	384 2.3×	75 0.6×	31 0.4×	13	629
Evridiki Michali Greece	8	369 1.1×	271 1.1×	214 1.3×	234 1.8×	172 2.1×	14	569
A. Zuiable United Kingdom	8	310 0.9×	94 0.4×	121 0.7×	46 0.4×	24 0.3×	13	348
Andrew Aw Canada	9	40 0.1×	37 0.2×	38 0.2×	144 1.1×	106 1.3×	21	272

Countries citing papers authored by Anna Hockaday

Since Specialization

Citations

This map shows the geographic impact of Anna Hockaday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Hockaday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Hockaday more than expected).

Fields of papers citing papers by Anna Hockaday

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Hockaday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Hockaday. The network helps show where Anna Hockaday may publish in the future.

Co-authorship network of co-authors of Anna Hockaday

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Hockaday. A scholar is included among the top collaborators of Anna Hockaday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Hockaday. Anna Hockaday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Slevin, Finbar, et al.. (2025). Radiating Excellence: A Decade of Pioneering Radiotherapy Trials and Collaborative Leadership at Leeds Cancer Research UK Clinical Trials Unit. Clinical Oncology. 47. 103937–103937.

Rawstron, Andy C., David Cairns, Nichola Webster, et al.. (2025). Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.. Blood. 146(Supplement 1). 794–794.

Dalal, Surita, Darren Newton, Nichola Webster, et al.. (2025). Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients. Blood. 146(Supplement 1). 796–796.

Jackson, Graham, Charlotte Pawlyn, Faith E. Davies, et al.. (2024). MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation. Blood. 144(Supplement 1). 3375–3375.

Cook, Gordon, A. John Ashcroft, Catherine Olivier, et al.. (2024). Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology. 11(11). e816–e829. 1 indexed citations

Pawlyn, Charlotte, Faith E. Davies, Gordon Cook, et al.. (2024). Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial. Blood. 144(Supplement 1). 1987–1987.

Tute, Ruth M. de, Charlotte Pawlyn, David A. Cairns, et al.. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 40(25). 2889–2900. 40 indexed citations

Jenner, Matthew, Charlotte Pawlyn, Faith E. Davies, et al.. (2022). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology. 201(2). 267–279. 11 indexed citations

Munir, Talha, Anna Hockaday, Dena Howard, et al.. (2022). Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology. 199(5). 707–719. 4 indexed citations

10.

Howard, Dena, Anna Hockaday, Julia Brown, et al.. (2021). A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials. 22(1). 38–38. 7 indexed citations

11.

Pepper, Andrea, Antonella Zucchetto, Kevin Norris, et al.. (2021). Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia. 36(1). 271–274. 4 indexed citations

12.

Drayson, Mark T., Gordon Cook, Faith E. Davies, et al.. (2021). Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment. Blood. 138(Supplement 1). 820–820. 5 indexed citations

13.

Cook, Gordon, Charlotte Pawlyn, Anna Hockaday, et al.. (2019). A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. The Lancet Haematology. 6(3). e154–e166. 75 indexed citations

14.

Striha, Alina, A. John Ashcroft, Anna Hockaday, et al.. (2018). The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials. 19(1). 169–169. 5 indexed citations

15.

Cook, Gordon, Christopher Parrish, Kwee Yong, et al.. (2018). Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. Blood. 132(Supplement 1). 255–255. 4 indexed citations

16.

Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 18(1). 387–387. 25 indexed citations

17.

Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 31(11). 2416–2425. 21 indexed citations

18.

Munir, Talha, Dena Howard, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 31(10). 2085–2093. 20 indexed citations

19.

Cook, Gordon, A. John Ashcroft, David A. Cairns, et al.. (2016). The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology. 3(7). e340–e351. 96 indexed citations

20.

Howard, Dena, Talha Munir, Anna Hockaday, et al.. (2016). Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials. 17(1). 456–456. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact